Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 09, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a specific employee retirement plan.
Material Changes
The primary material change reported is a reduction in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Previous Holding: 18,228,268 ADRs
- New Holding: 18,118,100 ADRs
- Change Date: May 05, 2005
- Average Price: $49.76
Management Commentary and Risks
The filing notes that the Plan is a discretionary fund where all employees or former employees are potential beneficiaries. Consequently, two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same manner as other employees. No specific risks, contingencies, or unusual items regarding the company's operations are disclosed in this text.
Investor Verification Points
- Verify the impact of the ADR reduction on the total outstanding share count.
- Confirm the specific ownership percentages of Dr. J P Garnier and Dr. T Yamada relative to the fund's holdings.
- Review the full Form 20-F for comprehensive financial performance data, as this 6-K contains only director interest disclosures.